Jul 10, 2024
Twice before WaveData to have looked into this subject only to find there is no link between product value and the delay in the introduction of Category M. However, time moves on, so we thought we’d repeat the analysis, partly because of a recent client request, and...
Jun 18, 2024
Prompted by a Client’s questions about Category M and the formula that goes behind it to drive Pharmacy profitability, we asked Charles Joynson, WaveData MD, to have a closer look at Category M to see if he can make any sense of it. Initially that we assumed that the...
Mar 7, 2024
We’ve read many articles from across the media about the ADHD drug shortage in recent weeks…… 💊 England has seen a sharp rise in the use of ADHD drugs, increasing by 11% per year between 2010 and 2019. This significant rise in reliance on...
Feb 27, 2024
In Parliament his month questions were posed to Andrew Stephenson, Secretary of State for Health and Social Care by Peter Grant MP (SNP). He asked ‘What steps the Department is taking to ensure that there is an adequate supply of Oxcarbazepine for patients with...
Feb 8, 2024
WaveData conducted a comparison of the average market prices given to accounts (pharmacies and dispensing doctors) by respiratory product manufacturers. The average discounts given over a 10 year period are very consistent at 9%, which probably reflects the underlying...
Nov 9, 2023
It would seem sensible to assume that profitable products are less likely to suffer shortages, concessions and price spikes than products where profit is hard to come by. Charles Joynson, WaveData MD, compared the reimbursement price and the average market price for...
